文献リスト

1) Lake KD. Immunosuppressive drugs and novel strategies to prevent acute and chronic allograft rejection. Semin Respir Crit Care Med. 2001; 22: 559-80

2) Demirkiran A, Hendrikx TK, Baan CC, et al. Impact of immunosuppressive drugs on CD4＋CD25＋FOXP3＋ regulatory T cells: does in vitro evidence translate to the clinical setting？ Transplantation. 2008; 85: 783-9

3) Korczak-Kowalska G, Wierzbicki P, Bocian K, et al. The influence of immuosuppressive therapy on the development of CD4＋CD25＋ T cells after renal transplantation. Transplant Proc. 2007; 39: 2721-3

4) Fellstrom B. Cyclosporine nephrotoxicity. Transplant Proc. 2004; 36: 220S-3S

5) Taylor JL, Palmer SM. Critical care perspective on immunotherapy in lung transplantation. J Intensive Care Med. 2006; 21: 327-44

6) Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant. 2005; 24: 119-30

7) Hausen B, Morris RE. Review of immunosuppression for lung transplantation. Novel drugs, new uses for conventional immunosuppressants, and alternative strategies. Clin Chest Med. 1997; 18: 353-66

8) Bush EL, Lin SS. Lung transplantation: advances in immunosuppression. Thorac Surg Clin. 2006; 16: 421-33

9) Colvin OM. An overview of cyclophosphamide development and clinical applications. Curr Pharm Des. 1999; 5: 555-60

10) Maltzman JS, Koretzky GA. Azathioprine: old drug, new actions. J Clin Invest. 2003; 111: 1122-4

11) Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol. 2005; 56: 23-46

12) Poppe D, Tiede I, Fritz G, et al. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-apc conjugation through inhibition of vav guanosine exchange activity on rac proteins. J Immunol. 2006; 176: 640-51

13) Tiede I, Fritz G, Strand S, et al. CD28-dependent rac1 activation is the molecular target of azathioprine in primary human CD4＋ T lymphocytes. J Clin Invest. 2003; 111: 1133-45

14) Brooks RJ, Dorr RT, Durie BG. Interaction of allopurinol with 6-mercaptopurine and azathioprine. Biomed Pharmacother. 1982; 36: 217-22

15) Coffey JJ, White CA, Lesk AB, et al. Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine (nsc 755) in cancer patients. Cancer Res. 1972; 32: 1283-9

16) Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst. 1999; 91: 2001-8

17) Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980; 32: 651-62

18) Holme SA, Duley JA, Sanderson J, et al. Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK. QJM. 2002; 95: 439-44

19) Reichenspurner H. Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant. 2005; 24: 119-30

20) Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 47: 85-118

21) Demirkiran A, Hendrikx TK, Baan CC, et al. Impact of immunosuppressive drugs on CD4＋CD25＋FOXP3＋ regulatory T cells: does in vitro evidence translate to the clinical setting？ Transplantation. 2008; 85: 783-9

22) Sollinger HW. Mycophenolates in transplantation. Clin Transplant. 2004; 18: 485-92

23) Saunders RN, Metcalfe MS, Nicholson ML. Rapamycin in transplantation: a review of the evidence. Kidney Int. 2001; 59: 3-16

24) Meyer NJ, Bhorade SM. Evolving immunosuppressive regimens for lung transplant recipients. Semin Respir Crit Care Med. 2006; 27: 470-9

25) Doyle RL, Hertz MI, Dunitz JM, et al. Rad in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis. J Heart Lung Transplant. 2001; 20: 330-9

26) Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006; 354: 2655-66

27) Poormoghim H, Moradi Lakeh M, Mohammadipour M, et al. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis. Rheumatol Int. 2011; 31: 1577-82

28) Tochimoto A, Kawaguchi Y, Hara M, et al. Efficacy and safety of intravenous cyclophosphamide pulse therapy with oral prednisolone in the treatment of interstitial lung disease with systemic sclerosis: 4-year follow-up. Mod Rheumatol. 2011; 21: 296-301

29) Nawata Y, Kurasawa K, Takabayashi K, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol. 1999; 26: 1527-33

30) Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005; 32: 1719-26

31) Miyake S, Ohtani Y, Sawada M, et al. Usefulness of cyclosporine A on rapidly progressive interstitial pneumonia in dermatomyositis. Sarcoidosis Vasc Diffuse Lung Dis. 2002; 19: 128-33

32) Dalkas MC, Illa I, Dambrosia JM, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993; 329: 1993-2000

33) Cherin P, Pelletier S, Teixeria P, et al. Result and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002; 46: 467-74

34) Danieli MG, Malcangi G, Palmieri C, et al. Cyclosporine A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis. Ann Rheum Dis. 2002; 61: 37-41

35) Guillevin L, Durand-Gasselin B, Cevallos R, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999; 42: pp. 421-30

36) Haworth SJ, Savage CO, Carr D, et al. Pulmonary haemorrhage complicating Wegener's granulomatosis and microscopic polyarteritis. Br Med J (Clin Res Ed). 1985; 290: 1775-8

37) Saxena R, Bygren P, Arvastson B, et al. Circulating autoantibodies as serological markers in the differential diagnosis of pulmonary renal syndrome. J Intern Med. 1995; 238: 143-52

38) Niles JL, Bottinger EP, Saurina GR, et al. The syndrome of lung hemorrhage and nephritis is usually an ANCA-associated condition. Arch Intern Med. 1996; 156 (4); 440-5

39) Cervera R, Bucciarelli S, Plasin MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS registry". J Autoimmun. 2009; 32 (3-4): 240-5

40) Chen M, Zhao MH. Severe pulmonary hemorrhage in patients with end-stage renal disease in antineutrophil cytoplasmic autoantibody-associated vasculitis. Am J Med Sci. 2009; 337: 411-4

41) Zamora MR, Warner ML, Tuder R. Diffuse alveolar hemorrhage and systemic lupus erythematosus clinical presentation, histology, survival, and outcome. Medicine (Baltimore). 1997; 76: 192-202

42) Gallagher H, Kwan JTC, Jayne DRW. Pulmonary renal syndrome: A 4-year, single-center experience. Am J Kidney Dis. 2002; 39: 42-7

43) Holguin F, Ramadan B, Gal AA, et al. Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis. Am J Med Sci. 2008; 336: 321-6

44) Lazor R, Bigay-Game L, Cottin V, et al. Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases, Medicine (Baltimore). 2007; 86: 181-93

45) Jayne D. Review article: progress of treatment in ANCA-associated vasculitis, Nephrology (Carlton). 2009; 14: 42-8

46) Jayne DRW, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007; 18: 2180-8

47) Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003; 349: 36-44

48) Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med. 2008; 359: 2790-803

49) Lee RW, D, Cruz DP. Pulmonary renal syndrome. Autoimmun Rev. 2010; 9: 657-60

50) Burton CM, Andersen CB, Jensen AS, et al. The incidence of acute cellular rejection after lung transplantation: a comparative study of anti-thymocyte globulin and daclizumab. J Heart Lung Transplant. 2006; 25: 638-47

51) Christie J, Edwards LB, Aurora P, et al. Registry of the international society for heart and lung transplantation: twenty-fifth official adult lung and heart/lung transplant report-2008. JHLT. 2007; 27: 957-69

52) Levine SM. A survey of clinical practice of lung transplantation in North America. Chest. 2004; 125: 1224-38

53) Iacono A, Johnson BA, Grgurich WF, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006; 12: 141-50

54) Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature. 1999: 397(6719): 530-4

55) Sato M, Tsujino I, Fukunaga M, et al. Cyclosporine A induces apoptosis of human lung adenocarcinoma cells via caspase-dependent pathway. Anticancer Res. 2011; 31: 2129-34

56) Keenan R, Iacono A, Dauber JH. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg. 1995; 60: 580-5

57) Zuckermann A, Reichenspurner H, Birsan T, et al. Cyclosporine A versus tacrolimus in combination with mycophenolate mofetil and steroids as primary immunosuppression after lung transplantation: one year results of a 2-center prospective randomized trial. J Thorac Cardiovasc Surg. 2003; 125: 891-900

58) Reichenspurner H, Glanville AR, Christina A, et al. Complete 3 year analysis of a prospective randomized international multi-center investigator driven study comparing tacrolimus and cyclosporin A, both in combination with MMF and steroids after lung transplantation in 249 patients. J Heart Lung Transplant. 2008; 27: S205-6

59) Reitz B, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med. 1982; 306: 557-64

60) Sollinger H. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U. S. renal transplant mycophenolate mofetil study group. Transplantation. 1995; 60: 225-32

61) Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate mofetil investigators. Transplantation. 1998; 27: 507-15

62) Palmer S, Baz MA, Sanders L, et al. Results of a randomized, prospective multicenter trial of mycophenolate mofetil versus azathioprine in the prevention of acute lung allograft rejection. Transplantation. 2001; 71: 1772-6

63) McNeil K, Glanville AR, Wahlers T, et al. Comparison of mycophenolate mofetil and azathioprine for prevention of bronchiolitis obliterans syndrome in de novo lung transplant recipients. Transplantation. 2006; 81: 998-1003

64) Troppmann C, Pierce JL, Gandhi MM, et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation. 2003; 76: 426-9

65) Bhorade SM, Baz M, Ahya V, et al. Comparison of tacrolimus/sirolimus/prednisone regimen versus tacrolimus/azathioprine/prednisone immunosuppressive regimen in lung transplantation. J Heart Lung Transplant. 2008; 27: S207

66) McWilliams T, Bronwyn JL, Russel PA, et al. Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation. J Heart Lung Transplant. 2003; 22: 210-3

67) Exposito V, de Prada JA, Gomez-Roman JJ, et al. Everolimus-related pulmonary toxicity in heart transplant recipients. J Heart Lung Transplant. 2008; 27: 797-800

68) Rehm B, Keller F, Mayer J. Resolution of sirolimus-induced pneumonitis after conversion to everolimus. Transplant Proc. 2006; 38: 711-3

69) Snell G, Valentine VG, Glanville AR, et al. Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial. Am J Transplant. 2006; 6: 169-77

70) Strader CR, Pearce CJ, Oberlies NH. Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite. J Nat Prod. 2011; 74: 900-7

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp